Lucid Diagnostics (LUCD) Stock Forecast, Price Target & Predictions
LUCD Stock Forecast
Lucid Diagnostics stock forecast is as follows: an average price target of $2.67 (represents a 154.29% upside from LUCD’s last price of $1.05) and a rating consensus of 'Buy', based on 3 wall street analysts offering a 1-year stock forecast.
LUCD Price Target
The average price target for Lucid Diagnostics (LUCD) is $2.67 based on 1-year price targets from 3 Wall Street analysts in the past 3 months, with a price target range of $3.00 to $2.50. This represents a potential 154.29% upside from LUCD's last price of $1.05.
LUCD Analyst Ratings
According to 3 Wall Street analysts, Lucid Diagnostics's rating consensus is 'Buy'. The analyst rating breakdown for LUCD stock is 0 'Strong Buy' (0.00%), 2 'Buy' (66.67%), 0 'Hold' (0.00%), 1 'Sell' (33.33%), and 0 'Strong Sell' (0.00%).
Lucid Diagnostics Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Nov 13, 2024 | Mike Matson | Needham | $2.50 | $0.79 | 216.46% | 138.10% |
| May 14, 2024 | Kyle Mikson | Canaccord Genuity | $3.00 | $0.95 | 215.79% | 185.71% |
| Apr 08, 2024 | Mark Massaro | BTIG | $2.50 | $0.93 | 169.48% | 138.10% |
| Nov 18, 2022 | - | BTIG | $3.50 | $1.91 | 83.25% | 233.33% |
| Nov 15, 2022 | - | Needham | $3.10 | $2.27 | 36.56% | 195.24% |
The latest Lucid Diagnostics stock forecast, released on Nov 13, 2024 by Mike Matson from Needham, set a price target of $2.50, which represents a 216.46% increase from the stock price at the time of the forecast ($0.79), and a 138.10% increase from LUCD last price ($1.05).
Lucid Diagnostics Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | 1 | 1 | 3 |
| Avg Price Target | $2.50 | $2.50 | $2.67 |
| Last Closing Price | $1.05 | $1.05 | $1.05 |
| Upside/Downside | 138.10% | 138.10% | 154.29% |
In the current month, the average price target of Lucid Diagnostics stock is $2.50, according to 1 Wall Street analyst offering twelve months forecast. The average price target represents a 138.10% increase as opposed to Lucid Diagnostics's last price of $1.05. This month's average price target is down 0.00% compared to last quarter, and down -6.37% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Oct 14, 2024 | BTIG | Buy | Buy | Hold |
| Apr 08, 2024 | BTIG | Buy | Buy | Hold |
| Nov 18, 2022 | BTIG | Buy | Buy | Hold |
| Nov 15, 2022 | Needham | Buy | Buy | Hold |
| Apr 26, 2022 | Zacks Investment Research | - | Sell | Downgrade |
Lucid Diagnostics's last stock rating was published by BTIG on Oct 14, 2024. The company gave LUCD a "Buy" rating, the same as its previous rate.
Lucid Diagnostics Financial Forecast
Lucid Diagnostics Revenue Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | $1.04M | $783.00K | $159.00M | $446.00K | $112.00K | $76.00K | - | $189.00K | $300.00K | $200.00K |
| Avg Forecast | $11.25M | $17.33M | $8.78M | $6.63M | $3.97M | $2.86M | $2.34M | $1.79M | $1.36M | $1.14M | $1.22M | $1.05M | $1.04M | $799.67K | $620.00K | $238.78K | $341.74K | $431.38K | $630.41K | $462.86K | $390.88K | $54.50K |
| High Forecast | $11.25M | $17.33M | $8.78M | $6.63M | $3.97M | $2.86M | $2.34M | $1.79M | $1.36M | $1.14M | $1.22M | $1.05M | $1.29M | $803.01K | $620.00K | $238.78K | $341.74K | $431.38K | $630.41K | $462.86K | $390.88K | $54.50K |
| Low Forecast | $11.25M | $17.33M | $8.78M | $6.63M | $3.97M | $2.86M | $2.34M | $1.79M | $1.36M | $1.14M | $1.22M | $1.05M | $891.43K | $796.34K | $620.00K | $238.78K | $341.74K | $431.38K | $630.41K | $462.86K | $390.88K | $54.50K |
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 3 | 1 | 3 | 6 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 3 | 3 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 1.00% | 0.98% | 256.45% | 1.87% | 0.33% | 0.18% | - | 0.41% | 0.77% | 3.67% |
Lucid Diagnostics's average Quarter revenue forecast for Mar 24 based on 3 analysts is $1.05M, with a low forecast of $1.05M, and a high forecast of $1.05M. LUCD's average Quarter revenue forecast represents a 0.77% increase compared to the company's last Quarter revenue of $1.04M (Dec 23).
Lucid Diagnostics EBITDA Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 3 | 1 | 3 | 6 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 3 | 3 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | $-10.82M | $-13.41M | $-11.58B | $-15.60M | $-14.31M | $-13.76M | $-13.92M | $-12.07M | $-11.24M | $-6.51M |
| Avg Forecast | $-2.25M | $-3.47M | $-1.76M | $-1.33M | $-793.42K | $-571.88K | $-467.64K | $-357.67K | $-271.86K | $-227.30K | $-244.53K | $-209.60K | $-208.00K | $-159.93K | $-124.00K | $-47.76K | $-68.35K | $-86.27K | $-126.08K | $-92.57K | $-78.17K | $-3.82B |
| High Forecast | $-2.25M | $-3.47M | $-1.76M | $-1.33M | $-793.42K | $-571.88K | $-467.64K | $-357.67K | $-271.86K | $-227.30K | $-244.49K | $-209.20K | $-178.28K | $-159.27K | $-124.00K | $-47.76K | $-68.35K | $-86.27K | $-126.08K | $-92.57K | $-78.17K | $-3.05B |
| Low Forecast | $-2.25M | $-3.47M | $-1.76M | $-1.33M | $-793.42K | $-571.88K | $-467.64K | $-357.67K | $-271.86K | $-227.30K | $-244.56K | $-210.00K | $-257.52K | $-160.60K | $-124.00K | $-47.76K | $-68.35K | $-86.27K | $-126.08K | $-92.57K | $-78.17K | $-4.58B |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 52.04% | 83.83% | 93420.11% | 326.71% | 209.42% | 159.45% | 110.41% | 130.42% | 143.78% | 0.00% |
undefined analysts predict LUCD's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Lucid Diagnostics's previous annual EBITDA (undefined) of $NaN.
Lucid Diagnostics Net Income Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 3 | 1 | 3 | 6 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 3 | 3 |
| Net Income | - | - | - | - | - | - | - | - | - | - | - | - | $-10.83M | $-14.21M | $-11.38B | $-1.98B | $-14.76M | $-14.35M | $-14.62M | $-12.44M | $-11.37M | $-7.40M |
| Avg Forecast | - | - | - | - | $-7.89M | $-8.06M | $-8.40M | $-8.56M | $-9.77M | $-10.38M | $-10.07M | $-12.09M | $-11.59M | $-11.96M | $-14.23M | $-16.38M | $-16.62M | $-16.93M | $-16.05M | $-12.51M | $-12.41M | $-3.59B |
| High Forecast | - | - | - | - | $-7.89M | $-8.06M | $-8.40M | $-8.56M | $-9.77M | $-10.38M | $-10.07M | $-12.09M | $-8.47M | $-11.96M | $-14.23M | $-16.38M | $-16.62M | $-16.93M | $-16.05M | $-12.51M | $-12.41M | $-2.87B |
| Low Forecast | - | - | - | - | $-7.89M | $-8.06M | $-8.40M | $-8.56M | $-9.77M | $-10.38M | $-10.07M | $-12.09M | $-13.37M | $-11.96M | $-14.23M | $-16.38M | $-16.62M | $-16.93M | $-16.05M | $-12.51M | $-12.41M | $-4.30B |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 0.93% | 1.19% | 799.75% | 120.83% | 0.89% | 0.85% | 0.91% | 0.99% | 0.92% | 0.00% |
Lucid Diagnostics's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. LUCD's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
Lucid Diagnostics SG&A Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 3 | 1 | 3 | 6 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 3 | 3 |
| SG&A | - | - | - | - | - | - | - | - | - | - | - | - | $8.49M | $8.16M | $7.86B | $10.64M | $10.47M | $9.59M | $11.18M | $9.04M | $7.62M | $4.38M |
| Avg Forecast | $355.82M | $548.26M | $277.88M | $209.81M | $125.51M | $90.46M | $73.97M | $56.58M | $43.00M | $35.96M | $38.68M | $33.16M | $32.90M | $25.30M | $19.62M | $7.55M | $10.81M | $13.65M | $19.94M | $14.64M | $12.37M | $1.72M |
| High Forecast | $355.82M | $548.26M | $277.88M | $209.81M | $125.51M | $90.46M | $73.97M | $56.58M | $43.00M | $35.96M | $38.69M | $33.22M | $40.74M | $25.41M | $19.62M | $7.55M | $10.81M | $13.65M | $19.94M | $14.64M | $12.37M | $1.72M |
| Low Forecast | $355.82M | $548.26M | $277.88M | $209.81M | $125.51M | $90.46M | $73.97M | $56.58M | $43.00M | $35.96M | $38.68M | $33.09M | $28.20M | $25.19M | $19.62M | $7.55M | $10.81M | $13.65M | $19.94M | $14.64M | $12.37M | $1.72M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 0.26% | 0.32% | 400.81% | 1.41% | 0.97% | 0.70% | 0.56% | 0.62% | 0.62% | 2.54% |
Lucid Diagnostics's average Quarter SG&A projection for Mar 24 is $33.16M, based on 3 Wall Street analysts, with a range of $33.09M to $33.22M. The forecast indicates a 290.57% rise compared to LUCD last annual SG&A of $8.49M (Dec 23).
Lucid Diagnostics EPS Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 3 | 1 | 3 | 6 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 3 | 3 |
| EPS | - | - | - | - | - | - | - | - | - | - | - | - | $-0.26 | $-0.34 | $-272.05 | $-48.31 | $-0.41 | $-0.39 | $-0.41 | $-0.35 | $-0.31 | $-0.20 |
| Avg Forecast | - | - | - | - | $-0.16 | $-0.16 | $-0.17 | $-0.17 | $-0.19 | $-0.21 | $-0.20 | $-0.24 | $-0.23 | $-0.24 | $-0.28 | $-0.33 | $-0.33 | $-0.35 | $-0.33 | $-0.26 | $-0.26 | $-0.29 |
| High Forecast | - | - | - | - | $-0.16 | $-0.16 | $-0.17 | $-0.17 | $-0.19 | $-0.21 | $-0.20 | $-0.24 | $-0.17 | $-0.24 | $-0.28 | $-0.33 | $-0.33 | $-0.35 | $-0.33 | $-0.26 | $-0.26 | $-0.29 |
| Low Forecast | - | - | - | - | $-0.16 | $-0.16 | $-0.17 | $-0.17 | $-0.19 | $-0.21 | $-0.20 | $-0.24 | $-0.27 | $-0.24 | $-0.28 | $-0.33 | $-0.33 | $-0.35 | $-0.33 | $-0.26 | $-0.26 | $-0.29 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 1.13% | 1.43% | 963.01% | 148.56% | 1.24% | 1.11% | 1.23% | 1.35% | 1.20% | 0.70% |
According to undefined Wall Street analysts, Lucid Diagnostics's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to LUCD previous annual EPS of $NaN (undefined).
Lucid Diagnostics Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| LUCD | Lucid Diagnostics | $1.05 | $2.67 | 154.29% | Buy |
| XAIR | Beyond Air | $0.48 | $1.00 | 108.33% | Buy |
| LUNG | Pulmonx | $6.72 | $11.93 | 77.53% | Buy |
| KIDS | OrthoPediatrics | $24.26 | $39.60 | 63.23% | Buy |
| NPCE | NeuroPace | $9.15 | $12.88 | 40.77% | Buy |
| LIVN | LivaNova | $53.58 | $70.50 | 31.58% | Buy |
| NARI | Inari Medical | $50.77 | $66.11 | 30.21% | Buy |
| OFIX | Orthofix Medical | $18.64 | $24.00 | 28.76% | - |
| CVRX | CVRx | $14.20 | $16.33 | 15.00% | Buy |
| FNA | Paragon 28 | $10.30 | $11.50 | 11.65% | Buy |
| CLPT | ClearPoint Neuro | $10.95 | $12.00 | 9.59% | Buy |
| IRMD | IRadimed | $55.45 | $60.00 | 8.21% | Buy |
| SRDX | Surmodics | $38.17 | $39.50 | 3.48% | Buy |
| ITGR | Integer | $137.56 | $138.00 | 0.32% | Buy |